K

Kiora Pharmaceuticals
D

KPRX

3.19000
USD
0.05
(1.59%)
مغلق
حجم التداول
451
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
9,709,904
أصول ذات صلة
ABBV
ABBV
-2.160
(-1.13%)
189.260 USD
ALNY
ALNY
-4.27
(-1.31%)
320.54 USD
AMGN
AMGN
-3.67
(-1.23%)
294.70 USD
AZN
AZN
-0.470
(-0.68%)
68.790 USD
GSK
GSK
-0.180
(-0.49%)
36.320 USD
MRK
MRK
-1.540
(-1.89%)
79.970 USD
MRNA
MRNA
-0.960
(-2.98%)
31.260 USD
PFE
PFE
-0.135
(-0.55%)
24.460 USD
REGN
REGN
-7.51
(-1.37%)
542.46 USD
المزيد
الأخبار المقالات

العنوان: Kiora Pharmaceuticals Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.